Browse drugs

…p=0.558). The main ARNI side effect was hypotension.Conclusions ARNI use was associated with favourable QoL, NYHA class, and LVEF as…

…nd 0.49 (95% CI 0.41 to 0.58) to 0.93 (95% CI 0.72 to 1.20) for SGLT2i. Prescriptions for both ARNi and SGLT2i showed a social gradien…

…e therapy at discharge in 2022. Prescription rates for ACEi/ARB/ARNI (67%), beta-blockers (89%), MRAs (40%), and SGLT2 inhibitors (4…

…e cotransporter-2 inhibitor (SGLT2i); and (v) ARNI, BB, MRA and SGLT2i. Baseline hospitalisation and mortality rates were informed by …

…the consolidation of four foundational pharmacological pillars: beta-blockers, renin-angiotensin system inhibitors or angiotensin receptor-ne…

… where only 4 patients had reasons specified for not continuing BBlocker, i.e. bradycardia or poor tolerance. There was no documentation…

…, 65% of patients were male. Median LVEF was 50% [IQR 41 – 56]. β-blockers were prescribed in 88.8% of patients, ARNI in 78.1%, MRAs in 45…

… of Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i). Use of Ivabradine (if heart rate ≥70 bpm in sinus rhythm) and hydralazine–isosorb…

…. 93% of patients were on beta blocker. 74% were on MRA, 74% on SGLT2i. 6 patients were readmitted to hospital from VW. The median NT …

…inhibitors or angiotensin receptor-neprilysin inhibitor (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucos…

…ibitor (SGLT2i), n (%) 43 (51.8) Loop diuretic, n (%) 55 (66.3) Amiodarone, n (%) 19 (22.9) Optimised on all heart failure medications, n …